MARKSANS2025-04-012025-06-30MARKSANS2025-06-30MARKSANS2025-04-012025-06-30in-capmkt:OtherExpenses1MemberMARKSANS2025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1MARKSANS2025-04-012025-06-30AuditorDomain1MARKSANS2025-06-30Statement1MARKSANS2025-04-012025-06-30Statement1MARKSANS2025-06-30StatementDynamic1I1Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares524404MARKSANSNOTLISTEDINE750C01026Marksans Pharma LimitedMain BoardEquity2025-04-012026-03-312025-08-122025-07-24INRMillionsQuarterlyFirst quarterSingle segmentPharmaceutical Formulation2025-08-1211:45:002025-08-1213:10:00Declaration of unmodified opiniontrue1falseThe Company has not defaulted on loans and debt securityand hence the disclosure is not applicable.2025-04-012025-06-30UnauditedStandalone31973400002010000032174400001452770000227980000-3291000027904000030200008188000056992000025817000006357400000635740000145380000980000015518000004805600000000480560000-76000047980000045316000011.061.06001.061.06Statutory Auditors of the Company have carried out limited review on the above results in terms of Regulation <BR> 33 of the SEBI Listing Obligation and Disclosure Requirements Regulations, 2015 the Regulation as <BR> amended and expressed an unmodified conclusion. <BR> <BR> The standalone unaudited financial results of the Company have been prepared in accordance with the <BR> recognition and measurement principles laid down in the Indian Accounting Standard 34 ‘Interim Financial <BR> Reporting, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued <BR> thereunder and other recognised accounting principles generally accepted in India and in terms of the <BR> Regulation. <BR> <BR> The figures for the quarter ended 31 March 2025 represent the derived figures between the audited figures in <BR> respect of full financial year ended 31 March 2025 and the unaudited published yearto date figures up to 31 <BR> December 2024, being the date of the end of third quarter of the financial year, which were subjected to a <BR> limited review by the statutory auditor of the Company. <BR> <BR> The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on <BR> Operating Segments <BR> <BR> Other income, net includes net loss on foreign exchange differences amounting to 37.73 million for the quarter <BR> ended 30 June 2025 31 March 2025 net gain of 25.80 million; 30 June 2024 net gain of 26.11 million; year <BR> ended 31 March 2025: net gain of 194.80 million. <BR> <BR> The above standalone unaudited financials results are available on the Company's website <BR> www.marksanspharma.com and stock exchanges websites, BSE www.bseindia.com and NSE <BR> www.nseindia.com, where the shares of the Company are listed.Other Expenses569920000Remeasurements of the net defined benefit liabilities/assets-1010000-1010000-250000-760000UnauditedtrueM S K A & Associates true2027-07-31Preferential Issues2023-01-1837240000002025-06-30falsefalseNANANAHarshvardhan PanigrahiCompany Secretary and Compliance OfficerMumbai2025-08-12The proceeds of the preferential issue are proposed to be used to strengthen the capital base and to enhance long term financial resources of the Company in order to fund expansion program of the CompanyNone3724000000035530000000No Deviations. <br></br> <br></br> Further please note that the funds are not raised during this quarter, and the reporting of the Statement of Deviation and Variation is being made for the funds raised in prior periods as mentioned.